Home/Day One Biopharmaceuticals/Jeremy Bender

JB

Jeremy Bender

Chief Executive Officer, President

Day One Biopharmaceuticals

Therapeutic Areas

Oncology Pediatric Oncology Neuro-Oncology

Day One Biopharmaceuticals Pipeline

Drug	Indication	Phase
OJEMDA™ (tovorafenib)	Pediatric low-grade glioma (pLGG) with BRAF alterations	Approved
Emi-Le	Undisclosed solid tumors (Novel ADC)	Phase 1

Leadership Team at Day One Biopharmaceuticals

Chief Medical Officer

Chief Development Officer

Michael Vasconelles

Senior Director, Market Planning

View full Day One Biopharmaceuticals profile